ARCHIVES

New Opportunities Still Abound In Immunology Program, Terry and other NCI Executives Say

This article is from The Cancer Letter archive.

Vol. 02 No. 09 | February 27, 1976

Download PDF Visit The Full Archive

Related Articles

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

In Brief: Outstanding Investigator Awards Draw 150 Letters Of Intent; Applications Due July 15

June 15, 1984

Cancer Center Planning Grants Recompetition Approved By Advisors

June 10, 1994

C. Gordon Zubrod, 84, Dies, Led Chemotherapy Research, Built Cooperative Group System

January 29, 1999

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

FDA orders “limited distribution” for lung cancer drug Iressa.

June 24, 2005